touchLearning Activities
Education, Conference Coverage and Articles
Longer diagnosis-to-ablation time (DAT) was associated with a higher risk of atrial arrhythmia recurrence following de novo radiofrequency catheter ablation (RFA) for atrial fibrillation (AF), according to a prospective, multicenter cohort study published in JAMA Network Open.1
Ionis Pharmaceuticals (Carlsbad, CA, USA) and AstraZeneca (Cambridge, UK) have announced that the phase 3 CARDIO-TTRansform trial (NCT04136171) of eplontersen (Wainua®; Ionis Pharmaceuticals and AstraZeneca) did not meet its primary efficacy endpoint in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
A new international expert consensus document has updated the universal definition of heart failure, with a greater focus on earlier detection, standardized classification and individualized risk reduction.
A proteomic analysis presented as late-breaking research at ENDO 2026 found that treatment with lorundrostat was associated with reductions in several circulating biomarkers linked to heart failure risk in patients with uncontrolled hypertension.
Long-term consumption of sugar-sweetened beverages and fruit juice, beginning in childhood, was associated with a higher likelihood of hypertension in adulthood, according to findings published in Circulation.
The American Heart Association (AHA), American College of Cardiology (ACC), American Diabetes Association (ADA) and American Society of Nephrology (ASN) have issued a new joint clinical practice guideline for the prevention, detection, evaluation and management of cardiovascular-kidney-metabolic (CKM) syndrome.
At EHRA 2026, Professor Claudio Tondo presents his highlights on advances in ablation and device technologies, led by pulsed field ablation, showcasing a rapidly evolving landscape in the treatment of complex arrhythmias.
Professor Amir Jadidi presented results from SOLVE-AF at EHRA 2026, showing that sinus rhythm–guided substrate ablation significantly improves outcomes in persistent AF patients with atrial fibrosis and supporting a more personalized ablation strategy.
touchCARDIO Future Leaders 2026 Following the successful introduction last year of our touchCARDIO Future Leaders, we are delighted to announce that nominations are now open for the 2026 edition. This initiative celebrates the next generation of pioneers in cardiology, those whose passion, ...
Your clinical career is shaped not only by what you know, but by who helps you navigate what comes next. Join us for the final episode in our mini-series exploring non-clinical skills that can help you thrive in your clinical ...
New late-breaking data presented on Day 3 of EuroPCR 2026 highlighted evolving approaches to antiplatelet therapy, transcatheter treatment of pure aortic regurgitation and procedural optimization in bicuspid TAVR
Day 2 hotline data at EuroPCR 2026 highlighted improved outcomes with FFR-guided PCI in TAVI, comparable 10-year survival with PCI and CABG in left main disease and consistent LAAC benefits across age groups.
Data presented on the first day of EuroPCR 2026, Paris, highlighted continued advances in lipid lowering, coronary scaffold technology and vessel restoration strategies. From substantial reductions in cardiovascular events with aggressive LDL-cholesterol lowering to encouraging long-term outcomes with next-generation bioresorbable and adaptive coronary devices, these studies offered important insights into the future direction of PCI and secondary prevention.
From ACC26, Dr Matt Budoff shared his highlights, including the new cholesterol guidelines and imaging advances position coronary artery calcium scoring at the heart of personalized cardiovascular risk assessment and prevention.
From breakthrough prevention strategies to pivotal late-breaking trials, ACC.26 showcased the rapidly evolving future of cardiovascular care.
At EHRA 2026, late-breaking trials across ablation, devices, and drug therapy signal major shifts in arrhythmia management, highlighting both rapid innovation and key unanswered questions. We spoke to Prof Jose Luis Merino for his highlights.
Presented at EHRA 2026 by Dr David Birnie, the OCEAN trial reveals low, brief atrial fibrillation recurrence rates after successful ablation - findings that may support selective anticoagulation discontinuation while reinforcing the need for ongoing follow-up.
From EHRA 2026, Dr Salik Ur Rehman discusses advances in pulsed field ablation, mapping technologies, and conduction system pacing highlight a rapidly evolving landscape in electrophysiology care.
touchCARDIO
Register Now!
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
- Save your progress for video
- Keep track of your CME credits
- Add personalised learning notes
- Receive updates from course leaders and faculty
- Be the first to hear about new and exciting interactive learning opportunities
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
